scholarly journals Overview of Neuropathic Pain Diagnosis and Assessment – An Approach Based on Mechanisms

10.5772/37126 ◽  
2012 ◽  
Author(s):  
Ioana Mindruta ◽  
Ana-Maria Cobzaru ◽  
Ovidiu Alexandru
Keyword(s):  
Neuropathic Pain ◽  
Pain Diagnosis

Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment

2010 ◽  
Vol 9 (8) ◽  
pp. 807-819 ◽  
Author(s):  
Ralf Baron ◽  
Andreas Binder ◽  
Gunnar Wasner
Keyword(s):  
Neuropathic Pain ◽  
Pathophysiological Mechanisms ◽  
Pain Diagnosis

Neuropathic pain: diagnosis and treatment

2013 ◽  
Vol 13 (5) ◽  
pp. 292-307 ◽  
Author(s):  
Francesca Magrinelli ◽  
Giampietro Zanette ◽  
Stefano Tamburin
Keyword(s):  
Neuropathic Pain ◽  
Diagnosis And Treatment ◽  
Pain Diagnosis

scholarly journals Pregabalin prescribing patterns in Australian general practice, 2012–2018: a cross-sectional study

BJGP Open ◽  
2020 ◽  
pp. bjgpopen20X101120 ◽  
Author(s):  
Andrea L Schaffer ◽  
Doreen Busingye ◽  
Kendal Chidwick ◽  
Jonathan Brett ◽  
Suzanne Blogg
Keyword(s):  
Chronic Pain ◽  
General Practice ◽  
Neuropathic Pain ◽  
Cross Sectional Study ◽  
Prescribing Patterns ◽  
Sectional Study ◽  
Cross Sectional ◽  
Pain Diagnosis ◽  
Australian General Practice ◽  
Recorded Diagnosis

BackgroundIn 2013 pregabalin was subsidised by Australia’s Pharmaceutical Benefits Scheme (PBS) for neuropathic pain. Since the subsidy, pregabalin prescribing has been increasing in Australia and so has related harm. There are concerns it is being prescribed for indications other than neuropathic pain, which have little evidence of efficacy.AimTo describe pregabalin prescribing in Australian general practice.Design & settingA cross-sectional study of patients attending 445 general practice sites in the national MedicineInsight database from March 2012–February 2018.MethodThe following aspects were calculated: the proportion of prescriptions that were for pregabalin per year; the prevalence of pain conditions in patients prescribed pregabalin; and same-day prescribing of pregabalin with opioids or benzodiazepines.ResultsPrescribing increased from 13 per 10 000 to 104 per 10 000 prescriptions between 2012–2013 and 2017–2018. A total of 1 891 623 patients were identified of whom 114 123 (6.0%) were prescribed pregabalin; 49.7% (n = 56 772) had a recorded diagnosis of neuropathic pain. Among people prescribed pregabalin without a recorded diagnosis of neuropathic pain, 43.5% (n = 24 927) had a diagnosis of back problems, 8.8% (n = 5073) chronic pain, and 26.4% (n = 30 146) had no pain diagnosis. Pregabalin was prescribed the same day as an opioid to 38.1% of patients (95% confidence interval [CI] = 37.1% to 39.1%) and a benzodiazepine to 13.1% of patients (95% CI = 12.5% to 13.7%). Patients with a diagnosis of chronic pain had the highest rate of same-day prescribing of pregabalin with an opioid (70.4%, 95% CI = 68.9% to 71.9%) or a benzodiazepine (25.8%, 95% CI = 24.2% to 27.4%)ConclusionSubstantial increases in pregabalin prescribing were identified in Australian general practice, but only half of patients had a neuropathic pain diagnosis recorded, the only approved indication for subsidy. High rates of same-day prescribing with opioids and benzodiazepines may put patients at increased risk of harm.

Sign in / Sign up

Export Citation Format

Share Document